Buy & Sell Apellis Pharmaceuticals Inc (APLS) – Apellis Pharmaceuticals Inc Price Today
Key Stats
- $5.25BMarket Cap
- HealthSector
- -18.02%3M Drawdown
- $5.32BEnterprise Value
- -Dividend Yield
- 12 daysTypical Hold Time
Apellis Pharmaceuticals Inc (APLS) is currently valued at a market capitalization of $5.25B, with an enterprise value of $5.32B. Over the past 52 weeks, Apellis Pharmaceuticals Inc has traded between a low of $16.93 and a high of $41.12, highlighting its annual price range. Over the past three months, Apellis Pharmaceuticals Inc has recorded a drawdown of -18.02%, reflecting recent price volatility. On average, investors hold Apellis Pharmaceuticals Inc for approximately 12 days, indicating typical investor behavior on the platform.
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science. It develops therapies for serious diseases, including the first-ever treatment for geographic atrophy, a leading cause of blindness.
Most Recent News
XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...

PAPZIMEOS shows 83% durable response in RRP patients with FDA granting 7-year market exclusivity
Precigen's PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), demonstrated durable complete responses in 83% of patients over at least 36 months without additional treatment. Five patients maintained responses b...
